---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-21-001027"
form_type: "8-K"
ticker: "EWTX"
cik: "0001710072"
company_name: "Edgewise Therapeutics, Inc."
filed_at: "2021-08-09T23:59:59+00:00"
generated_at: "2026-06-29T18:59:13.141595+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Edgewise Therapeutics Q2 net loss $10.4M; cash $299M; EDG-5506 advancing

## Summary
- Net loss of $10.4M ($0.21 per share) for Q2 2021, up from $4.0M loss in Q2 2020; R&D expenses $7.9M.
- Cash and marketable securities of $299M as of June 30, 2021, funding pipeline through key milestones.
- EDG-5506 Phase 1 MAD study ongoing; topline data from healthy volunteers and Becker patients expected late 2021.
- Preclinical EDG-002 cardiac modulator for hypertrophic cardiomyopathy progressing with encouraging data.

## SEC filing metadata
- accession: 0001157523-21-001027
- form_type: 8-K
- ticker: EWTX
- cik: 0001710072
- company_name: Edgewise Therapeutics, Inc.
- filed_at: 2021-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710072/000115752321001027/0001157523-21-001027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710072/000115752321001027/a52473423.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-21-001027
- JSON: https://secwatch.observer/filing/0001157523-21-001027.json
- Plain text: https://secwatch.observer/filing/0001157523-21-001027.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.